title: Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas.
abstract: Seventeen patients less than or equal to 20 years of age with newly diagnosed (n = 10) or recurrent (n = 7) malignant gliomas (anaplastic astrocytoma and glioblastoma multiforme) were treated with cyclophosphamide in association with hematopoietic cytokines (GM-CSF or G-CSF). Cyclophosphamide was given at a dose of 2 g/m2 daily for 2 days at 4-week intervals. Toxicity consisted of grade IV neutropenia and thrombocytopenia in 95% and 48% of cycles, respectively. There were no cyclophosphamide-related cardiac, pulmonary, or urothelial toxicities observed. Four of 10 patients with newly diagnosed disease demonstrated responses (three complete and one partial responses; one CR was only of 2 months duration). None of the seven patients with recurrent tumors demonstrated a response. We conclude that high-dose cyclophosphamide warrants further evaluation in children with newly diagnosed malignant glioma.
authors.affiliation: Department of Pediatrics, Hôpital Sainte-Justine, Montreal, Canada.
authors.forename: G B
authors.initials: GB
authors.lastname: McCowage
authors.forename: H S
authors.initials: HS
authors.lastname: Friedman
authors.forename: A
authors.initials: A
authors.lastname: Moghrabi
authors.forename: T
authors.initials: T
authors.lastname: Kerby
authors.forename: L
authors.initials: L
authors.lastname: Ferrell
authors.forename: E
authors.initials: E
authors.lastname: Stewart
authors.forename: M
authors.initials: M
authors.lastname: Duncan-Brown
authors.forename: H E
authors.initials: HE
authors.lastname: Fuchs
authors.forename: R
authors.initials: R
authors.lastname: Tien
authors.forename: R E
authors.initials: RE
authors.lastname: McLendon
authors.forename: L
authors.initials: L
authors.lastname: Meier
authors.forename: J
authors.initials: J
authors.lastname: Kurtzberg
authors.forename: D
authors.initials: D
authors.lastname: Ashley
authors.forename: O M
authors.initials: OM
authors.lastname: Colvin
authors.forename: D C
authors.initials: DC
authors.lastname: Longee
mesh_terms: D000293:Adolescent; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide